Results 71 to 80 of about 2,385 (197)

Effect of platelet inhibition with cangrelor during PCI on ischemic events [PDF]

, 2013
Item does not contain fulltextBACKGROUND: The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications.
Prats, Jayne, Bramucci, Ezio, Gibson, C.M., Price, Matthew J., McLaurin, B.T., Gallup D., Leonardi, Sergio, Tauth J., Angiolillo, Dominick J., Skerjanec, Simona, Gibson C. M., Tousek, F., Prats, J., Spriggs, D., Radke, P.W., McLaurin, Brent T., Hamm C. W., Hamm, C.W., Spriggs D., Stone, G.W., Bhatt, Deepak L., Todd, M., Gallup, D., Harrington, R.A., White H. D., Tauth, J., Stone, Gregg W., Steg P. G., Spriggs, Douglas, Leonardi S., Liu T., Généreux, Philippe, Radke P. W., Steg, P. Gabriel, et al., Skerjanec, S., Radke, Peter W., Harrington R. A., Gibson, C. Michael, Gallup, Dianne, Todd M., Hamm, Christian W., Tousek F., Prats J., Leonardi, S., Liu, T., Tousek, Frantisek, Liu, Tiepu, McLaurin B. T., Widimsky, P., Bramucci, E., Tauth, Jeffrey, Mahaffey, K.W., Mahaffey K. W., Stone G. W., Bramucci E., Widimsky P., Widimský, Petr, Angiolillo D. J., Price, M.J., Angiolillo, D.J., Genereux, P., White, Harvey D., Skerjanec S., Todd, Meredith, Verheugt, F.W., Bhatt, D.L., Bhatt D. L., Harrington, Robert A., Mahaffey, Kenneth W., Price M. J., White, H.D., Steg, P.G., Genereux P.   +73 more
core   +1 more source

Percutaneous mechanical circulatory support for acute right heart failure: A practical approach

ESC Heart Failure, Volume 12, Issue 4, Page 2652-2668, August 2025.
This is an overview of percutaneous mechanical circulatory support options for acute right heart failure, illustrating key clinical scenarios, device types, and principles of tailored device selection based on haemodynamics and underlying pathology. Abstract Acute right heart failure (RHF) represents a critical entity with significant morbidity and ...
Mario Gramegna, Christophe Vandenbriele, Guido Tavazzi, Mir B. Basir, Caroline Bleakley, Mario Iannaccone, Daniel Kretzschmar, Francesco Maisano, Anna Mara Scandroglio, Benedikt Schrage, P. Christian Schultze, Gregory Serrao, Matthew Tomey, Richard Trimlett, Dirk Westermann, Matteo Montorfano, George Dangas, Susanna Price, Alaide Chieffo   +18 more
wiley   +1 more source

Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives [PDF]

, 2018
Cangrelor is an intravenously administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action. In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without ...
Sfantou, D., Lekakis, J., Alexopoulos, D., Pappas, C.   +3 more
core  

Progress on the development of Class A GPCR‐biased ligands

British Journal of Pharmacology, Volume 182, Issue 14, Page 3249-3300, July 2025.
Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales, Magdalena M. Scharf, Marcel Bermudez, Attila Egyed, Rafael Franco, Olivia K. Hansen, Nadine Jagerovic, Jan Jakubík, György M. Keserű, Dóra Judit Kiss, Pawel Kozielewicz, Olav Larsen, Maria Majellaro, Ana Mallo‐Abreu, Gemma Navarro, Rubén Prieto‐Díaz, Mette M. Rosenkilde, Eddy Sotelo, Holger Stark, Tobias Werner, Laura M. Wingler   +20 more
wiley   +1 more source

Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers

American Journal of Hematology, Volume 100, Issue 4, Page 561-574, April 2025.
ABSTRACT The objective of this study was to investigate the characteristics and trends of therapeutic errors in non‐healthcare facility settings associated with antithrombotic medications reported to United States Poison Centers by analyzing data from the National Poison Data System from 2000 to 2021.
Emma N. Cravo, Hannah L. Hays, Jaahnavi Badeti, Henry A. Spiller, Natalie I. Rine, Motao Zhu, Gary A. Smith   +6 more
wiley   +1 more source

High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies

Research and Practice in Thrombosis and Haemostasis, 2020
In a high‐risk patient with subacute heparin‐induced thrombocytopenia (HIT) type A (platelet count recovery following acute HIT but with persisting platelet‐activating antibodies), in whom urgent cardiac surgery was required, a key clinical question ...
Andreas Koster, Ishac Nazy, Ingvild E. Birschmann, James W. Smith, Jo‐Ann I. Sheppard, Theodore E. Warkentin   +5 more
doaj   +1 more source

Impact of Mild Hypothermia As Adjunctive Therapy in Patients With ST‐Elevation Myocardial Infarction: A Meta‐Analysis and Trial Sequential Analysis of Randomized Controlled Trials

Catheterization and Cardiovascular Interventions, Volume 105, Issue 3, Page 543-556, February 15, 2025.
ABSTRACT Background The prevention of reperfusion injury remains an unmet need in ST‐elevation myocardial infarction (STEMI) patients. Several randomized controlled trials (RCTs) evaluated mild hypothermia as adjunctive therapy during STEMI, with conflicting results.
Renzo Laborante, Donato Antonio Paglianiti, Mattia Galli, Giuseppe Patti, Domenico D'Amario   +4 more
wiley   +1 more source

Cangrelor Attenuates Coated-Platelet Formation [PDF]

Clinical and Applied Thrombosis/Hemostasis, 2008
P2Y 12 inhibitors were introduced clinically as effective inhibitors of adenosine-5′-diphosphate (ADP) mediated platelet activation and aggregation. This class of pharmacological agents has enjoyed considerable success. Cangrelor is a recently developed P2Y 12
Nicholas B, Norgard, Callie L, Hann, George L, Dale   +2 more
openaire   +2 more sources

Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease: A Systematic Review

CNS Neuroscience &Therapeutics, Volume 31, Issue 2, February 2025.
Antiplatelet drugs are essential for treating atherosclerotic vascular disease (ASVD), but drug interactions can lead to resistance and affect therapeutic efficacy. Due to the complexity of treatments in ASVD patients, understanding these interactions is critical for optimizing therapy and reducing adverse effects.
Xiangqian Huang, Jiahao Song, Xiaoming Zhang, Mengqi Wang, Yuchuan Ding, Xunming Ji, Da Zhou, Ran Meng   +7 more
wiley   +1 more source

Therapeutic Potential of Gasdermin D‐Mediated Myocardial Pyroptosis in Ischaemic Heart Disease: Expanding the Paradigm From Bench to Clinical Insights

Journal of Cellular and Molecular Medicine, Volume 29, Issue 3, February 2025.
ABSTRACT Ischaemic heart disease (IHD) remains a leading cause of global morbidity and mortality. One significant contributor to the pathology of IHD is the excessive release of inflammatory mediators during the disease progression. Pyroptosis is a form of programmed cell death (PCD) triggered by the activation of inflammasomes and caspase 1.
Chanon Piamsiri, Chayodom Maneechote, Siriporn C. Chattipakorn, Nipon Chattipakorn   +3 more
wiley   +1 more source